Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend by 9% to twelve cents per ... with the dividend payable on September 22, 2014 to ... September 8, 2014. About Kewaunee Scientific ... Corporation is a recognized global leader in the design, ...
(Date:8/27/2014)... N.J. and NINGBO, China ... and the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today ... the development of generic pharmaceuticals, primarily targeting ... of the agreement, Amerigen and Menovo will jointly develop ... United States . Menovo will be responsible for ...
(Date:8/27/2014)... 27, 2014 Ambit Biosciences (Nasdaq: AMBI ), ... targeting unmet needs in oncology, autoimmune and inflammatory disease, today ... Conference to be held at The New York Palace Hotel ... 3-4, 2014. Alan Fuhrman , Ambit,s CFO, ... drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Inc. (NYSE Amex: INO ), which is advancing ... that Dr. J. Joseph Kim, President and CEO, will present ... Healthcare Conference taking place December 13-14 at the Waldorf-Astoria in ... 13 10:50 am ET A live and archived ...
... Dec. 11, 2011   TetraLogic Pharmaceuticals , a biopharmaceutical ... treat cancer, today announced the oral presentation of new ... the 53rd ASH Annual Meeting and Exposition in San ... M. D. Anderson Cancer Center, demonstrated that TL32711 induces ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting 2
(Date:8/27/2014)... DiaSorin has announced that their new webinar , ... guest speaker Dr. Gregory A. Plotnikoff, a physician and ... Integrative Medicine. Dr. Plotnikoff serves as an integrative medicine ... Healing and as Senior Consultant, Center for Health Care ... as a co-editor of the new journal Global Advances ...
(Date:8/27/2014)... August 28, 2014 National Resident ... in the Association for Medical Education in Europe (AMEE) ... Milan, Italy August 30 – September 3, 2014. ... the international medical education community, share the benefits of ... strengthen resident physician placement in countries throughout the world. ...
(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as ... an exclusive ranking of the nation’s fastest-growing privately held ... the most important segment of the economy - America’s ... as members of the Inc. 500 list include Dell, ... of world’s greatest companies have had their start on ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Reviewing the ... will now be easier for the public when using ... that are promoted in all 50 states in the ... , The different insurers that are generating the rates ... possible for adults to use the programmed system without ...
Breaking Medicine News(10 mins):Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2
... Pacific Dental Services (PDS(TM)) provided dentistry to the Community of ... Los Angeles , Over 250 employees, affiliated dentists and family members helped those ... in need , World Impact, Inc.(C) was a ... ...
... obesity epidemic in explaining the troubling trend , , TUESDAY, ... pronounced reduction in risk factors for heart disease is ... that the trend has flattened, starting at the beginning ... date back a fair amount of time, but now ...
... 11 The number of heart attack patients,admitted to ... smoking ban were implemented, according to a Henry Ford,Hospital ... hospital admissions from,1999-2006 in Michigan for what is known ... a smoking ban could lead to 3,340 fewer,admissions annually., ...
... Anthem Blue Cross and,Blue Shield in Maine is ranked ... according to the current (Nov. 17) issue of U.S. ... recognition as,one of the nation,s best health plans is ... member satisfaction and NCQA,accreditation., "We work hard to ...
... in Thermotherapy, ALAMEDA, Calif. and PITTSBURGH, Nov. ... today the introduction of ReBound, a new and,innovative ... and joint contractures using radio frequency (RF) diathermy. ... treatment systems,to the physical therapy and athletic training ...
... and prevention, new report finds , , TUESDAY, Nov. 11 ... of educational materials, and meager data collection are hindering ... driving in the United States and aggressively tackle the ... Foundation (NSF) released its findings Tuesday as part of ...
Cached Medicine News:Health News:Watts Powerhouse Church Receives a Facelift Through the Volunteers of Pacific Dental Services(R) 2Health News:Watts Powerhouse Church Receives a Facelift Through the Volunteers of Pacific Dental Services(R) 3Health News:After Decades, Decreases in Heart Risk Factors Level Off 2Health News:Study: Smoking Ban Would Help Reduce Heart Attack Admissions 2Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 4Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 5Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 6Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 7Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 8Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 9Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 2Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 3Health News:States Asleep at the Wheel in Fighting Drowsy Driving 2
... from Poly (L-Lactic Acid) material which has ... fixation throughout the healing process. The ... it is absorbed into the tissue or ... press-fit anchor design allows for accurate placement ...
... better. How can one of the leading ... becoming more convenient to use in all ... TwinFix Suture Anchor with Needles combines the ... and timesaving anchor inserter and needle delivery ...
... Anchor is the smallest, strongest anchor ... in placement into even the smallest ... 3-0 or 4-0 ETHIBOND EXCEL suture ... cutting swaged needles. The kit includes ...
... Threaded Anchors (3.0mm) are ideal for soft tissue ... surgical applications. The FASTIN threaded anchor technology offers ... surgical sites. If you need a threaded anchor ... the FASTIN anchor is the anchor for you. ...
Medicine Products: